Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation

RT @JorgeAlatorreA1: We know that #mEGFR tumors present with low #MTB, are less inflammatory and have low expression of #PDL1. We must expe…

We know that #mEGFR tumors present with low #MTB, are less inflammatory and have low expression of #PDL1. We must expect further results from #RCT to see if these pts really benefit from #IO. ➡️Read article: https://t.co/2Vk0lzy12M Dr. Jorge A. Alatorre A

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation: Purpose, To evaluate the outcomes of immune checkpoint inhibitor (ICI)-based treatments #oncology… https://t.co/uHkJ9y

RT @FrontOncology: New research: Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistanc…